Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $31.5 million.

  • Collegium Pharmaceutical's Income towards Parent Company rose 23751.47% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 3403.28%. This contributed to the annual value of $42.4 million for FY2024, which is 788.23% down from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Income towards Parent Company stood at $31.5 million, which was up 23751.47% from $12.0 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Income towards Parent Company ranged from a high of $72.8 million in Q2 2021 and a low of -$25.0 million during Q4 2021
  • In the last 5 years, Collegium Pharmaceutical's Income towards Parent Company had a median value of $12.0 million in 2025 and averaged $11.0 million.
  • Within the past 5 years, the most significant YoY rise in Collegium Pharmaceutical's Income towards Parent Company was 757745.1% (2021), while the steepest drop was 45978.73% (2021).
  • Over the past 5 years, Collegium Pharmaceutical's Income towards Parent Company (Quarter) stood at -$25.0 million in 2021, then soared by 71.24% to -$7.2 million in 2022, then skyrocketed by 543.67% to $31.9 million in 2023, then tumbled by 60.75% to $12.5 million in 2024, then surged by 151.33% to $31.5 million in 2025.
  • Its last three reported values are $31.5 million in Q3 2025, $12.0 million for Q2 2025, and $2.4 million during Q1 2025.